Cyclacel Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CYCC

*Your capital is at risk

$6.37

+0 (+0%)

At Close: Dec 10, 2025

Cyclacel Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 27.27. In total, the insiders bought 412.36M and sold 390.43M CYCC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	27.27
● Buy	412.36M shares
● Sell	390.43M shares
88% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 26, 2025 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 27.27. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 05, 2025 Sell	Common Stock S-Sale	Kua Khai Loon 10 Percent Owner	10% Owner	19 054 Value: $133.6K
Sep 05, 2025 Sell	Common Stock S-Sale	Kua Khai Loon 10 Percent Owner	10% Owner	19 054 Value: $133.6K
Sep 04, 2025 Buy	Common Stock J-Other	Yap Kim Choy 10 Percent Owner	10% Owner	186 465 Value: $1.39M
Sep 04, 2025 Sell	Series C Common Stock Warrants J-Other	Yap Kim Choy 10 Percent Owner	10% Owner	186 465 Value: $1.90M
Sep 04, 2025 Buy	Common Stock J-Other	Kua Khai Loon 10 Percent Owner	10% Owner	186 465 Value: $1.39M
Sep 04, 2025 Sell	Series C Common Stock Warrants J-Other	Kua Khai Loon 10 Percent Owner	10% Owner	186 465 Value: $1.90M
Sep 04, 2025 Buy	Common Stock J-Other	Ong Yee Lung 10 Percent Owner	10% Owner	186 465 Value: $1.39M
Sep 04, 2025 Sell	Series C Common Stock Warrants J-Other	Ong Yee Lung 10 Percent Owner	10% Owner	186 465 Value: $1.90M
Sep 04, 2025 Sell	Series C Common Stock Warrants J-Other	Kua Khai Loon 10 Percent Owner	10% Owner	186 465 Value: $1.90M
Sep 04, 2025 Buy	Common Stock J-Other	Kua Khai Loon 10 Percent Owner	10% Owner	186 465 Value: $1.39M
Sep 04, 2025 Sell	Series C Common Stock Warrants J-Other	Yap Kim Choy 10 Percent Owner	10% Owner	186 465 Value: $1.90M
Sep 04, 2025 Buy	Common Stock J-Other	Yap Kim Choy 10 Percent Owner	10% Owner	186 465 Value: $1.39M
Sep 04, 2025 Sell	Series C Common Stock Warrants J-Other	Ong Yee Lung 10 Percent Owner	10% Owner	186 465 Value: $1.90M
Sep 04, 2025 Buy	Common Stock J-Other	Ong Yee Lung 10 Percent Owner	10% Owner	186 465 Value: $1.39M
Sep 01, 2025 Buy	Common Stock	Ong Yee Lung 10 Percent Owner	10% Owner	0 Value: $0
Sep 01, 2025 Buy	Common Stock	Kua Khai Loon 10 Percent Owner	10% Owner	0 Value: $0
Sep 01, 2025 Buy	Common Stock	Yap Kim Choy 10 Percent Owner	10% Owner	0 Value: $0
Sep 01, 2025 Buy	Common Stock	Yap Kim Choy 10 Percent Owner	10% Owner	0 Value: $0
Sep 01, 2025 Buy	Common Stock	Kua Khai Loon 10 Percent Owner	10% Owner	0 Value: $0
Sep 01, 2025 Buy	Common Stock	Ong Yee Lung 10 Percent Owner	10% Owner	0 Value: $0
Jul 30, 2025 Sell	Common Stock S-Sale	Lazar David E. 10 Percent Owner	10% Owner	6 750 Value: $83.4K
Jul 30, 2025 Sell	Common Stock S-Sale	Lazar David E. 10 Percent Owner	10% Owner	6 750 Value: $83.4K
Jun 20, 2025 Buy	Series A Common Stock Warrants	Ong Yee Lung 10 Percent Owner	10% Owner	218 000 Value: $1.67M
Jun 20, 2025 Buy	Series B Common Stock Warrants	Ong Yee Lung 10 Percent Owner	10% Owner	218 000 Value: $1.96M
Jun 20, 2025 Buy	Series C Common Stock Warrants	Ong Yee Lung 10 Percent Owner	10% Owner	218 000 Value: $2.22M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYCLACEL PHARMACEUTICALS

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...

Read Full Profile Here